RT @SCIDirector: SCI member Michael Snyder & colleagues found NEOPS, a composite neoantigen presentation score, to be a robust, novel bioma…
RT @SCIDirector: SCI member Michael Snyder & colleagues found NEOPS, a composite neoantigen presentation score, to be a robust, novel bioma…
RT @SCIDirector: SCI member Michael Snyder & colleagues found NEOPS, a composite neoantigen presentation score, to be a robust, novel bioma…
SCI member Michael Snyder & colleagues found NEOPS, a composite neoantigen presentation score, to be a robust, novel biomarker of #immunecheckpointblockade response in #melanoma. @SnyderShot @CCR_AACR https://t.co/6NAYTtnXJD
Prediction of #Immunotherapy Response in Melanoma through Combined Modeling of #Neoantigen Burden & Immune-Related Resistance Mechanisms https://t.co/iHFO0OZYgD "modeling tumor & immune-related molecular mechanisms using both exome & transcript
Data presented in Clinical Cancer Research demonstrated that NEOPS™, our composite neoantigen-based #biomarker, outperformed single-analyte biomarkers, such as TMB, in a cohort of patients with late-stage #melanoma. Learn more: https://t.co/y1wbCWC7rT #Imm
RT @RobotRrid: RRIDs were included in the Clinical Cancer Research paper "Prediction of Immunotherapy Response in Melanoma t…" (https://t.c…
RT @RobotRrid: RRIDs were included in the Clinical Cancer Research paper "Prediction of Immunotherapy Response in Melanoma t…" (https://t.c…
RRIDs were included in the Clinical Cancer Research paper "Prediction of Immunotherapy Response in Melanoma t…" (https://t.co/63nKnFHjLk). RRIDs like this improve reproducibility in scientific research. #methodsmatter #OpenScience
RRIDs were included in the Clinical Cancer Research paper "Prediction of Immunotherapy Response in Melanoma t…" (https://t.co/63nKnFHjLk). Thank you for making your #methodsmatter. #STMpublishing
RT @PersonalisInc: Our composite biomarker, NEOPS™, proved the statistically strongest #biomarker compared with all single-gene biomarkers,…
RT @PersonalisInc: Our composite biomarker, NEOPS™, proved the statistically strongest #biomarker compared with all single-gene biomarkers,…
Our composite biomarker, NEOPS™, proved the statistically strongest #biomarker compared with all single-gene biomarkers, expression signatures, and TMB biomarkers evaluated in a cohort of melanoma patients. Learn more from our recent publication: https://t
"Neoantigen presentation score (NEOPS) incorporates damaging events in the antigen presentation machinery with predicted neoantigens to stratify patient response to immunotherapy... supporting the [clinical] use of whole-exome & whole-transcriptome dat
🆕“NEOPS proved the statistically strongest biomarker compared with all single-gene biomarkers, expression signatures & TMB biomarkers evaluated in this cohort. Subsequent..suggests that NEOPS is a robust, novel biomarker of ICB response in melanoma” $P
PSNLのImmunoID NeXTを用いて計測するバイオマーカーNEOPスコアが、チェックポイント阻害剤が有効な癌患者を現在の標準のTMBよりも正確に予測したという研究結果。(アブストラクトしか読んでいません。) https://t.co/CF1tNeZGL1
In a publication for Clinical Cancer Research, we evaluate the predictive strength of our composite #biomarker, NEOPS™, in a cohort of melanoma patients. Learn more about our integrative, multi-omic biomarker approach: https://t.co/DUHFeYUtgb #ImmunoTherap
RT @drnicolson: This work evaluates the predictive strength of a composite biomarker, neoantigen presentation score (NEOPS), in a cohort of…
Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms https://t.co/EFP8T2yoiV https://t.co/VKkXWDLbnd
This work evaluates the predictive strength of a composite biomarker, neoantigen presentation score (NEOPS), in a cohort of patients with late-stage melanoma. NEOPS proved the statistically strongest biomarker compared with all si…https://t.co/C4NRy4ooTZ
New article: Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms https://t.co/pOHTtGaYh9 #melanoma #oncology https://t.co/nPOkASXbl7
Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms https://t.co/T4Q70sYZy7